



April 23 – 27 | New Orleans, La.

2023 Reviewing Codes

One (1) Reviewing Code that best describes the content of your abstract must be selected during abstract submission

- | | |
|--|---|
| 1200 Advanced imaging: Adaptive optics – VI | 1500 Cataract surgery: Outcomes and epidemiology – LE |
| 1210 Advanced imaging: Clinical applications – VI | 1510 Cataract surgery: Surgical techniques – LE |
| 1220 Advanced imaging: Functional imaging – VI | 1520 Cataract, cornea and anterior segment: Epidemiology – CL |
| 1230 Advanced imaging: Retinal activity, visual function, and performance – VI | 1530 Cataractogenesis: Pathobiology and genetics – LE |
| 1240 AI in the retina – RE | 1540 Cataractogenesis: Prevention and treatment – LE |
| 1250 Allergic conjunctivitis – IM | 1550 Cell therapy – RC |
| 1260 Amblyopia – EY | 1560 Central visual pathways: Structure and function – VN |
| 1270 AMD & non AMD retinal degeneration immunobiology – IM | 1570 Choroidal neovascularization – RC |
| 1280 AMD anti VEGF – RE | 1580 Clinical/Epidemiologic Research: Other – CL |
| 1290 AMD imaging – RE | 1590 Color vision – VI |
| 1300 AMD: Biochemical and molecular disease mechanisms – AP | 1600 Conjunctiva: Cell biology, disease, and surgery – CO |
| 1310 AMD: Cell biology – RC | 1610 Contact lens – CO |
| 1320 AMD: Clinical research – RE | 1620 Cornea surgery: Refractive – CO |
| 1330 AMD: Epidemiology – CL | 1630 Cornea: Other – CO |
| 1340 AMD: New drugs, delivery systems, and mechanisms of action – PH | 1640 Corneal biomechanics – CO |
| 1350 AMD: Pathology – RC | 1650 Corneal cell and molecular biology – CO |
| 1360 AMD: Preclinical studies – RC | 1660 Corneal development and cell differentiation – CO |
| 1370 AMD: Translational studies – RE | 1670 Corneal disease: Pharmacology – PH |
| 1380 Anatomy and Pathology/Oncology: Other – AP | 1680 Corneal endothelium – CO |
| 1390 Anatomy: Ocular structures in myopia excepting cornea, lens, retina – AP | 1690 Corneal epithelial wound repair and healing – CO |
| 1400 Anterior segment and ocular surface omics and genetics – GEN | 1700 Corneal epithelium – CO |
| 1410 Anti inflammatory agents, antibiotics, and antivirals – PH | 1710 Corneal imaging – CO |
| 1420 Antimicrobial resistance and antimicrobial agents – IM | 1720 Corneal immunology – CO |
| 1430 Aqueous humor dynamics – PH | 1730 Corneal neovascularization – CO |
| 1440 Big data – CL | 1740 Corneal neuropathy and ocular pain – CO |
| 1450 Biochemistry/Molecular Biology: Other – BI | 1750 Corneal stroma: Keratocytes, wound repair and healing – CO |
| 1460 Bioinformatics, biostatistics and multi-omics – GEN | 1760 Corneal surgery: Non refractive – CO |
| 1470 Blood flow – PH | 1770 Corneal tissue engineering and regenerative medicine – CO |
| 1480 Blood retina barrier – RC | 1780 Cytokines and growth factors – PH |
| 1490 Cataract surgery: Novel designs and treatments – LE | 1790 Data-guided functional systems biology – GEN |
| | 1800 Development of the eye – VI |
| | 1810 Diabetic macular edema anti VEGF – RE |

- 1820 Diabetic macular edema: Clinical research – RE
1830 Diabetic retinopathy immunology – IM
1840 Diabetic retinopathy: Biochemical and molecular disease mechanisms – BI
1850 Diabetic retinopathy: Epidemiology – CL
1860 Diabetic retinopathy: Medical – RE
1870 Diabetic retinopathy: Pharmacological agents, targets, and mechanisms of action – PH
1880 DR: Mechanism and preclinical studies – RC
1890 Drug delivery: Iris ciliary body/intraocular fluids/posterior segment – PH
1900 Dry eye, clinical – CO
1910 Dry eye, non clinical – CO
1920 Electroretinography of disease – VN
1930 Electroretinography: Basic mechanisms and techniques – VN
1940 Endophthalmitis: Clinical – RE
1950 Extraocular muscles and associated tissues – EY
1960 Eye movements – EY
1970 Eye Movements/Strabismus/Amblyopia/Neuro-Ophthalmology: Other – EY
1980 Ganglion cell structure and function – VN
1990 Gene editing – BI
2000 Gene therapy, cell-based therapy, and other novel therapeutics – BI
2010 Gene transfer and editing: for therapy – RC
2020 Gene variants: Sequencing, function, or phenotype – BI
2030 Genetics Cross-sectional group: Other – GEN
2040 Genetics or omics powered bioinformatic applications – GEN
2050 Genome structure, functional/translational genomics, transcriptomics – BI
2060 Glaucoma immunology – IM
2070 Glaucoma omics and genetics – GEN
2080 Glaucoma: Animal models – GL
2090 Glaucoma: Aqueous humor dynamics, trabecular meshwork and ciliary body – GL
2100 Glaucoma: Biochemistry and molecular biology, genomics and proteomics – BI
2110 Glaucoma: Biomechanics – BI
2120 Glaucoma: Cellular mechanisms in the conventional outflow pathway – GL
2130 Glaucoma: Clinical drug studies and clinical trials – GL
2140 Glaucoma: Data science, machine learning, and artificial intelligence – GL
2150 Glaucoma: Epidemiology – CL
2160 Glaucoma: IOP measurement and characterization – GL
2170 Glaucoma: Laser therapy – GL
2180 Glaucoma: Neurodegeneration – GL
2190 Glaucoma: Neuroprotection and neuroregeneration – GL
2200 Glaucoma: Neuroregeneration and regenerative therapies (stem cell/cell based/organoids) – GL
2210 Glaucoma: Ocular blood flow – GL
2220 Glaucoma: Other – GL
- 2230 Glaucoma: Structure/function relationships – GL
2240 Glaucoma: Surgery or wound healing – GL
2250 Glaucoma: Visual fields and psychophysics – GL
2260 Glial cell biology and neuron-glia interactions – RC
2270 Health care delivery and economic research – CL
2280 Imaging: Adaptive optics – MOI
2290 Imaging: Animal models and molecular imaging – MOI
2300 Imaging: Anterior segment – MOI
2310 Imaging: Functional imaging – MOI
2320 Imaging: Gene therapy and delivery – MOI
2330 Imaging: Image processing and interpretation – MOI
2340 Imaging: Machine learning others – MOI
2350 Imaging: Machine learning for classification – MOI
2360 Imaging: Machine learning for segmentation – MOI
2370 Imaging: MRI and ultrasound – MOI
2380 Imaging: New imaging biomarkers – MOI
2390 Imaging: OCT angiography clinical applications – MOI
2400 Imaging: OCT angiography new development and technical improvements – MOI
2410 Imaging: OCT Clinical application – MOI
2420 Imaging: OCT new development & technical improvement – MOI
2430 Imaging: OCTA angiography preclinical applications – MOI
2440 Imaging: Other technologies and developments – MOI
2450 Imaging: Posterior segment, clinical – RE
2460 Immunology/Microbiology: Other – IM
2470 Inner plexiform layer, synapses, circuits, and processing – VN
2480 Intraocular pressure/physiology pharmacology – PH
2490 Intravitreal/periocular local therapies (excluding anti VEGF) – RE
2500 Ischemia/reperfusion, hypoxia and oxidative stress – PH
2510 Keratitis: Clinical – CO
2520 Keratitis: Laboratory research – CO
2530 Keratoconus and collagen crosslinking – CO
2540 Lacrimal gland and meibomian gland (only cornea, not neuro ophthalmology) – CO
2550 Laser – RE
2560 Lens cytoskeleton, biomechanics and optics – LE
2570 Lens development and differentiation – LE
2580 Lens epithelium – LE
2590 Lens physiology – LE
2600 Lens proteins: Normal and pathogenic biochemistry – LE
2610 Lens: Other – LE
2620 Low Vision Cross-sectional group: Other – LV
2630 Low vision rehabilitation services – LV
2640 Machine learning in vision sciences – VI
2650 Macular diseases excluding AMD – RE
2660 Macular edema – RE
2670 Microbial Infection and Immunity – IM
2680 Microbiology/immunology translational – IM

- 2690 Microbiome and ocular immunology – IM
 2700 Mobility and driving – LV
 2710 Molecular and biochemical mechanisms of ocular disease – BI
 2720 Multidisciplinary Ophthalmic Imaging Cross-sectional group:
 Other – MOI
 2730 Myopia: Animal experimental models – AP
 2740 Myopia: Epidemiology – CL
 2750 Myopia: Genetics and environment – AP
 2760 Myopia: Imaging – AP
 2770 Myopia: Mechanisms for emmetropization and anomalies – AP
 2780 Myopia: Ocular biometric index – AP
 2790 Myopia: Ocular dimensions and models – VI
 2800 Myopia: Physiological optics and image quality – VI
 2810 Myopia: Retina/RPE/choroid/sclera – AP
 2820 Myopia: Structure/function relationships – AP
 2830 Myopia: Vision – VI
 2840 Neural retina: Cell biology – RC
 2850 Neural retina: Dysfunction in disease – VN
 2860 Neuro ophthalmology – EY
 2870 Neuro ophthalmology: Papilledema – EY
 2880 Neuro ophthalmology: Pediatric – EY
 2890 Neuro ophthalmology: Pupillometry – EY
 2900 Neuroprotection – PH
 2910 Neuroprotection – RC
 2920 Next generation sequencing and computational analyses – BI
 2930 Non AMD retinal disease: Epidemiology – CL
 2940 Non infectious cornea/ocular surface immunology – IM
 2950 Non infectious uveitis – IM
 2960 Novel genomics computational methods, AI and deep learning – GEN
 2970 Ocular embryology and development – AP
 2980 Ocular immune homeostasis – IM
 2990 Ocular proteomics, lipidomics, metabolomics, and systems biology – BI
 3000 Ocular surface health/disease and microbiome – CO
 3010 Ocular toxicology – PH
 3020 Ocular trauma: Epidemiology – CL
 3030 Oculoplastics – EY
 3040 Oncology: Investigative approaches – Proteomic, genomic, and experimental models – AP
 3050 Oncology: Ocular tumors - Pathology, cytology, and diagnostic and prognostic approaches – AP
 3060 Oncology: Retinoblastoma – AP
 3070 Oncology: Therapeutics – Ocular and systemic toxicities and complications of cancer therapies – AP
 3080 Oncology: Uveal melanoma – AP
 3090 Ophthalmology training/education – CL
 3100 Optics: Biometry, modelling and optical design – VI
 3110 Optics: Cornea and astigmatism – VI
- 3120 Optics: Crystalline lens and accommodation – VI
 3130 Optics: Intraocular lenses – VI
 3140 Optics: Retina – VI
 3150 Optics: Visual function and performance – VI
 3160 Optics: Wavefront aberrations, refractive corrections and adaptive optics – VI
 3170 Outer plexiform layer synapses, circuits, and processing – VN
 3180 Pathology/Oncology: Melanocytic lesions – Benign and malignant melanocytic lesions of the globe, orbit, ocular adnexa, and ocular surface except for uveal melanomas – AP
 3190 Pathology/Oncology: Non-melanocytic lesions – Benign and malignant nonmelanocytic lesions of the globe, orbit, ocular adnexa, and ocular surface – AP
 3200 Pathology: Choroid – Mechanisms in health and disease – AP
 3210 Pathology: Mechanism of disease and disease modeling excluding ocular tumors – AP
 3220 Pediatric ophthalmology – EY
 3230 Pediatric ophthalmology: Epidemiology – CL
 3240 Pediatric ophthalmology: Imaging – EY
 3250 Performance assessment & questionnaires – LV
 3260 Phenomics, causal inference and other genetics-powered bioinformatic applications – GEN
 3270 Photoreceptors: Cell biology – RC
 3280 Photoreceptors: Degeneration/cell death – RC
 3290 Photoreceptors: Structure and function – VN
 3300 Physiology/Pharmacology: Other – PH
 3310 Posterior capsular opacification (PCO) and lens fibrosis – LE
 3320 Presbyopia and the aging eye – VI
 3330 Proliferative vitreoretinopathy – RE
 3340 Public health – CL
 3350 Quality of life – LV
 3360 Reading – LV
 3370 Refractive error: Epidemiology – BI
 3380 Retina degeneration: Acquired – RC
 3390 Retina degeneration: Hereditary – RC
 3400 Retina/RPE omics and genetics – GEN
 3410 Retina/RPE: Biochemistry and molecular biology – BI
 3420 Retina/RPE: Metabolism – PH
 3430 Retina/RPE: New drugs, mechanisms of action, and toxicity – PH
 3440 Retina/RPE: Transplantation, clinical – RE
 3450 Retina: Development – RC
 3460 Retina: Functional testing/evaluation – RE
 3470 Retina: Lipid metabolism – RC
 3480 Retina: Metabolism – RC
 3490 Retina: Neural repair and remodeling – VN
 3500 Retina: Other – RE
 3510 Retina: Physiology/pharmacology – PH
 3520 Retinal adaptation and circadian rhythms – VN
 3530 Retinal Cell Biology: Other – RC
 3540 Retinal detachment: Clinical – RE

- 3550 Retinal prostheses – RE
3560 Retinal vascular diseases (excluding diabetic retinopathy) – RE
3570 Retinitis pigmentosa: Clinical – RE
3580 Retinoids and carotenoids: Phototransduction, visual cycle and macular pigment – BI
3590 Retinopathy of prematurity: Clinical – RE
3600 ROP: Mechanism and preclinical studies – RC
3610 RPE and choroid: Cell biology – RC
3620 Stem cells and disease modeling in vitro – RC
3630 Stem cells and gene therapy: Clinical – RE
3640 Strabismus – EY
3650 Strabismus: Therapeutic approaches and clinical trials – EY
3660 System-wide application or methods development for genetics or omics – GEN
3670 Tear film – CO
3680 Teleophthalmology/telemedicine for eye diseases – CL
3690 Thyroid eye disease – EY
3700 Transgenic models – RC
3710 Trauma: Posterior segment, clinical – RE
3720 Uveitis: Epidemiology, quality of life – IM
- 3730 Uveitis: Therapeutics – IM
3740 Vasculature inner retina, pericytes and angiogenesis – RC
3750 Virtual and augmented reality: Visual and optical factors – VI
3760 Virtual reality and eye tracking – LV
3770 Vision restoration – LV
3780 Visual and retinal processing – VN
3790 Visual function and quality of life – CL
3800 Visual function: Binocular vision – VI
3810 Visual function: Normal vision, aging and impairment – VI
3820 Visual function: Perception and adaptation – VI
3830 Visual impairment and function – LV
3840 Visual impairment: Epidemiology – CL
3850 Visual Neuroscience: Other – VN
3860 Visual Psychophysics/Physiological Optics: Other – VI
3870 Visual psychophysics: Fundamental and applied – VI
3880 Visual psychophysics: Spatial and temporal vision – VI
3890 Vitreoretinal interface disease – RE
3900 Vitreoretinal surgery: Clinical – RE
3910 Vitreoretinal surgery: Novel approaches – RE